Press release
GM2 Gangliosidosis Market is projected to reach USD 332 million by 2034
GM2 Gangliosidosis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913
GM2 gangliosidosis is a fatal, inherited lysosomal disorder caused by deficiency of β-hexosaminidase A (Tay-Sachs) or both A and B enzymes (Sandhoff). This leads to toxic accumulation of GM2 gangliosides in neurons, resulting in progressive neurodegeneration. With no current cure, there remains an immense unmet need for disease-modifying therapies.
Key Market Highlights
• 2024 Market Size: USD 152 million
• 2034 Forecast: USD 332 million
• CAGR (2025-2034): 8.1%
• Largest Segment: Gene therapy candidates
• Fastest-Growing Segment: Early diagnosis & newborn screening programs
Epidemiology & Clinical Insights
1. Disease Spectrum
GM2 gangliosidosis includes:
• Tay-Sachs disease (TSD) - HEXA deficiency
• Sandhoff disease (SD) - HEXA & HEXB deficiency
• GM2 activator deficiency - rarest form
2. Prevalence
• Infantile form: most common and severe
• Estimated global incidence: 1 in 100,000-300,000 births
• Higher carrier rates in certain populations (Ashkenazi Jewish, French-Canadian, Cajun)
3. Clinical Presentation
• Developmental regression
• Neurodegeneration
• Hypotonia
• Seizures
• Cherry-red spot on retina
• Progressive loss of motor and cognitive function
4. Diagnostics
• Enzyme assays
• Genetic testing (HEXA, HEXB mutations)
• Neuroimaging
• Newborn screening (emerging)
Market Growth Drivers
1. Rapid Progress in Gene Therapy
AAV-based and lentiviral therapies targeting HEXA/HEXB deficiencies show strong potential.
2. Increasing Global Awareness & Screening
Expanded carrier screening and newborn screening programs improve early detection.
3. Strong Rare Disease Funding & Incentives
Orphan drug designations, fast-track approvals, and government support drive R&D.
4. Emerging CNS Drug Delivery Technologies
Novel delivery techniques (intrathecal, intraventricular, BBB-penetrating vectors) increase efficacy.
5. Expanded Access to Genetic Counseling
Growing network of rare disease centers supports early diagnosis and patient enrollment in trials.
Market Restraints
• Extremely rare prevalence limits large clinical trials
• High cost of gene therapies
• Challenges delivering therapies across the blood-brain barrier
• Limited long-term efficacy data
Market Opportunities
1. AAV9 & AAVrh10 Vector Gene Therapies
Promise improved CNS penetration and durable enzyme expression.
2. Substrate Reduction Therapy (SRT)
Oral small molecules reducing glycosphingolipid accumulation.
3. Enzyme Replacement Therapy (ERT) Innovation
Next-generation recombinant enzymes with improved CNS targeting.
4. CRISPR & Gene-Editing Platforms
Long-term correction of HEXA/HEXB mutations.
5. Combination Therapies
Potential synergy between gene therapy + SRT + neuroprotective treatments.
Segmentation Overview
By Disease Type
• Tay-Sachs disease
• Sandhoff disease
• GM2 activator deficiency
By Therapy Type
• Gene therapy (AAV-based, lentiviral)
• Substrate reduction therapy
• Enzyme replacement therapy
• Small molecule therapies
• Supportive/palliative care
By Patient Type
• Infantile
• Juvenile
• Adult-onset
By Diagnostics
• Molecular genetic testing
• Enzyme analysis
• Newborn screening panels
By End User
• Hospitals
• Rare disease centers
• Specialty clinics
• Research institutions
Explore Full Report here: https://exactitudeconsultancy.com/reports/70913/gm2-gangliosidosis-market
Regional Insights
North America - Largest Market
Advanced gene therapy R&D, NIH-funded trials, and strong rare disease infrastructure.
Europe - Strong Research Ecosystem
Germany, France, UK, and the Netherlands lead in genomics and LSD clinical trials.
Asia Pacific - Fastest Growing
Increasing investment in gene therapy manufacturing and rare disease diagnostics.
Latin America - Developing
Expanding access to genetic testing and newborn screening.
Middle East & Africa - Emerging
Improved rare disease awareness and expansion of tertiary care centers.
Competitive Landscape
Key companies and research institutions driving GM2 gangliosidosis therapy development include:
• Axovant Gene Therapies (Sio Gene Therapies) - AAV9-based AXO-AAV-GM2
• Passage Bio - PBGM01 (AAV-delivered gene therapy)
• CAMP4 Therapeutics - RNA-based gene upregulation
• Prevail Therapeutics (Eli Lilly)
• BioMarin
• Genzyme / Sanofi
• JCR Pharmaceuticals
• Academic collaborations (UMass, NIH, CHOP, McGill)
Focus areas include AAV gene delivery, BBB-penetrating vectors, enzyme replacement innovations, and neuroprotective strategies.
Recent Market Developments
• Promising early-stage results from AAV9 gene therapy trials
• FDA and EMA orphan drug designations for multiple pipeline candidates
• Growing use of intrathecal delivery for CNS targeting
• Expanded newborn screening proposals for GM2 disorders
• Increased global patient registry enrollment improving trial readiness
Future Outlook (2025-2034)
The GM2 Gangliosidosis Market will expand significantly as:
• Gene therapy becomes central to treatment
• Early diagnosis improves through newborn screening
• CRISPR and novel vectors progress into clinical use
• Global funding for rare diseases increases
By 2034, the market is expected to reach USD 332 million, driven by breakthrough innovation in gene therapy and strengthened rare disease infrastructure.
This report is also available in the following languages : Japanese (GM2ガングリオシドーシス), Korean (GM2 강글리오시도시스), Chinese (GM2神经节苷脂病), French (Gangliosidose GM2), German (GM2-Gangliosidose), and Italian (Gangliosidosi GM2), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/70913
Our More Reports:
GM1 Gangliosidosis Market
https://exactitudeconsultancy.com/reports/71034/gm1-gangliosidosis-market
Granzyme B Antibody Market
https://exactitudeconsultancy.com/reports/66261/granzyme-b-antibody-market
Granzyme H Antibody Market
https://exactitudeconsultancy.com/reports/66262/granzyme-h-antibody-market
Anti-Nestin Antibody Market
https://exactitudeconsultancy.com/reports/66265/anti-nestin-antibody-market
Anti-Neuropilin-1 Antibody Market
https://exactitudeconsultancy.com/reports/66266/anti-neuropilin-1-antibody-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM2 Gangliosidosis Market is projected to reach USD 332 million by 2034 here
News-ID: 4311448 • Views: …
More Releases from Exactitude Consultancy
Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitatio …
The global cold planer market is experiencing steady growth as governments and private contractors increase spending on road rehabilitation, resurfacing, and infrastructure modernization. Cold planers, also known as milling machines, are widely used to remove damaged asphalt and concrete surfaces efficiently, supporting sustainable road construction practices.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68250
Key Market Highlights
• Increasing focus on road maintenance and resurfacing projects
• Growing demand for efficient and precision milling…
Credit Management Software Market Accelerates as Organizations Focus on Risk Mit …
The global credit management software market is witnessing robust growth as organizations across industries adopt digital solutions to manage credit risk, improve receivables performance, and strengthen financial controls. Credit management software enables businesses to automate credit scoring, monitor customer creditworthiness, and streamline collections processes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68248
Key Market Highlights
• Growing adoption of automated credit risk assessment tools
• Increasing focus on working capital and cash flow management
• Integration…
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Oper …
The global session border controller (SBC) market is experiencing strong growth as telecom operators and enterprises increasingly deploy SBC solutions to secure, manage, and optimize real-time IP communications. SBCs play a critical role in protecting voice over IP (VoIP), unified communications (UC), and multimedia sessions from cyber threats while ensuring interoperability and quality of service.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68246
Key Market Highlights
• Growing adoption of VoIP and…
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Tr …
The global biofuel market, encompassing e-methane, sustainable aviation fuel (SAF), and other advanced biofuels, is witnessing robust growth as governments and industries intensify efforts to reduce carbon emissions and transition toward cleaner energy sources. These fuels play a critical role in achieving net-zero targets while enabling decarbonization of hard-to-abate sectors such as aviation, shipping, and heavy transportation.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68244
Key Market Highlights
• Rapid growth of…
More Releases for GM2
GM2 Gangliosidosis Market to Witness Promising Upswing by 2034, DelveInsight For …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
GM2 Gangliosidosis Market Outlook, Trends, Therapies and Growth Forecast
GM2 gangliosidosis is a group of rare, inherited lysosomal storage disorders caused by mutations in the HEXA, HEXB, or GM2A genes, leading to defective β-hexosaminidase enzyme activity. This results in the accumulation of GM2 ganglioside in neurons, causing progressive neurodegeneration. The most common forms include Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913
Although rare, GM2 gangliosidosis represents a critical unmet need…
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approv …
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and…
GM2 Gangliosidosis Market Set to Advance Through 2034, Fueled by Gene Therapy In …
GM2 Gangliosidosis refers to a group of rare, inherited lysosomal storage disorders-including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency-caused by mutations that impair the breakdown of GM2 gangliosides in nerve cells. These disorders are characterized by progressive neurodegeneration, muscle weakness, motor impairment, seizures, and early mortality, especially in infantile-onset forms. The most common types, Tay-Sachs and Sandhoff disease, result from mutations in the HEXA and HEXB genes, respectively.
DelveInsight's report,…
GM2 Gangliosidosis Pipeline Overview: 8+ Innovative Therapies Driving Hope in Ra …
The therapeutic landscape for GM2 gangliosidosis-an ultra-rare, inherited lysosomal storage disorder encompassing Tay-Sachs and Sandhoff diseases-is witnessing growing innovation, with the pipeline evolving toward more disease-modifying and potentially curative therapies. GM2 gangliosidosis is caused by mutations affecting β-hexosaminidase A and/or B enzymes, resulting in the toxic accumulation of GM2 gangliosides in neurons, which leads to progressive neurodegeneration. Despite the severity of this disease, current management remains largely supportive, highlighting an…
GM2 Gangliosidosis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging …
GM2 Gangliosidosis pipeline constitutes 8+ key companies continuously working towards developing 8+ GM2 Gangliosidosis treatment therapies, analyzes DelveInsight
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic…
